Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Sulcus-based enhancement of visual quality

The portfolio of 1stQ AddOn® IOLs from Medicontur allows surgeons to provide high-quality vision for patients seeking to reduce spectacle dependence for distance or for a full range of vision. Available in refractive, toric, trifocal, and trifocal toric models, the 1stQ AddOn® portfolio offers opportunities to correct residual refractive error or upgrade to presbyopia correction in pseudophakic patients. In addition, the use of the trifocal and trifocal toric models in a planned dual procedure gives cataract surgery patients the benefit of presbyopia correction while allowing for simple reversibility if they are unhappy with the results or develop incompatible pathology in the future.

The 1stQ AddOn® supplementary IOL platform has acquired a long track record of efficacy and safety. The current version of the lens was first implanted in Europe in 2010. Today, the 1stQ AddOn® lenses are available in 48 countries and for more than a decade in most.

Designed by German engineer Rudiger Dworschak, the 1stQ AddOn® platform was created to overcome the risks associated with IOL placement in the ciliary sulcus. Its unique 4-flex haptic configuration maintains positional stability. Features of both the haptics and optic design serve to maintain iris function, anterior segment physiology, and clearance between the AddOn® and  intracapsular IOL.

Clinical experience with the 1stQ AddOn® IOLs establishes their safety, demonstrates the predictability of the refractive outcomes, and documents their ability to provide high level visual acuity and quality. Further data on outcomes with secondary implantation of the 1stQ AddOn® trifocal or trifocal toric IOL to correct residual spherical refractive error, astigmatism, and presbyopia in pseudophakic patients is being collected in a prospective, multinational clinical trial underway in six centers in Europe.

To read more about the design, implantation, and outcomes of the 1stQ AddOn® IOLs:

More information

>Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Ophthalmologist site. It’s FREE!

Login
Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Company Information

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register